American Origin Unverified
This profile is unclaimed and has not been independently reviewed.
Claim & get verified
SANGAMO THERAPEUTICS, INC
$0.17
-20.00%
OTC: SGMO · 15-min delayed
$39.6MRevenue · FY2025
-$122.9MNet income
SGMOOTC
About SANGAMO THERAPEUTICS, INC
SANGAMO THERAPEUTICS INC
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Reported figures
Financial summary
- Revenue FY2025
- $39.6M
- Net income
- -$122.9M
- Total assets
- $59.7M
- Operating margin
- -306.5%
- Net margin
- -310.8%
Source: SEC EDGAR · updated Jun 7, 2026
Multi-year
Revenue & profit trend
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue Net income
FY 2025
Financial statements
Income statement
- Revenue
- $39.6M
- Operating expenses
- $160.8M
- Operating income
- -$121.2M
- Income tax
- -$568.0K
- Net income
- -$122.9M
- EPS (basic)
- $-0.44
- EPS (diluted)
- $-0.44
Balance sheet
- Total assets
- $59.7M
- Current assets
- $35.8M
- Total liabilities
- $74.0M
- Current liabilities
- $42.5M
- Shareholders’ equity
- -$14.3M
Cash flow
- Operating cash flow
- -$97.2M
- Investing cash flow
- -$102.0K
- Financing cash flow
- $70.7M
- Net cash flow
- -$22.5M
Statements via Polygon.io (SEC filings)
- EPS (diluted)
- $-0.44
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
Market data by Polygon.io · prices are 15-minute delayed
Auto-generated
At a glance
- Reported a net loss of $122.9M in FY2025.
- Revenue declined 64% from FY2021 to FY2025.
- Trading 77% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review SANGAMO THERAPEUTICS, INC.
Write a review
Newsroom
News about SANGAMO THERAPEUTICS, INC
Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends
US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being'
Cell and Gene Therapies in Rare Disorders Market to Skyrocket Across the 7MM During the Forecast Period (2025–2034) | DelveInsight
Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
mRNA Therapeutics Market Size to Hit USD 48.65 Billion by 2032 due to Advances in Cancer Treatment and Expanding mRNA Vaccine Applications | Research by SNS Insider
News & sentiment via Polygon.io
Explore
Browse all →
